SMAD3 and cancer: The TGF‐β signaling pathway is widely recognized as an important mechanism regulating EMT in various cancers [64], promoting mesenchymal transition by activating downstream effector molecules such as SMAD2 and SMAD3, which coordinate a series of transcriptional programs driving tumor cell migration, invasion, and immune evasion [65, 66].